HydroGraph Clean Power Inc., a commercial manufacturer of nanomaterials, announced that its flagship graphene product, FGA-1, has been successfully trialed in Hawkeye Bio’s biomedical sensor aimed at the early detection of lung cancer. The global biosensor market is expected to reach US$60 billion by 2032.

HydroGraph’s graphene, the third company to be certified globally by the Graphene Council, was selected by Hawkeye Bio based on the purity and consistency of its graphene. Headquartered in Toronto, HydroGraph’s manufacturing facility is located in Manhattan, Kan.

Hawkeye Bio, a medical technology company based in Los Angeles, developed the novel sensor technology that detects the activity of enzymes, as opposed to quantity of enzymes, enabling improved detection of chronic inflammatory diseases, such as cancer or autoimmunity. The sensor also improves the patient experience by using non-invasive biological samples, such as blood, urine, saliva or exhaled breath, in early-stage lung cancer testing.  Read more.